Pfizer (NYSE: PFE)’s marketing authorization applications for maraviroc in the United States and Europe will receive accelerated reviews.
Once approved, maraviroc will become the first in a new class of HIV/AIDS drugs called CCR5 antagonists that work by blocking viral entry.
According to John LaMattina, president, Pfizer Global Research and Development:
"There is a profound global need for new medicines to help HIV/AIDS patients. We expect that CCR5 antagonists, like maraviroc, will become critically important new treatment options for patients who are resistant or intolerant to their current HIV/AIDS therapies."
Accelerated reviews are granted to potential medicines that, will provide significant improvement ot current therapies once approved.
Find more details from the press release.
[Photo Credit: images.scotsman.com]
Comment Preview